Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis

@article{Risch2020EarlyOT,
  title={Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis},
  author={H. Risch},
  journal={American Journal of Epidemiology},
  year={2020}
}
  • H. Risch
  • Published 2020
  • Medicine
  • American Journal of Epidemiology
Abstract More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. Remdesivir has shown mild effectiveness in hospitalized… Expand
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
TLDR
Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly fewer hospitalizations. Expand
Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis
TLDR
This work adds to the growing literature of studies that have found substantial benefit for use of HCQ combined with other agents in the early outpatient treatment of COVID-19, and adds the possibility of steroid use to enhance treatment efficacy. Expand
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
TLDR
Key pathophysiological principles that relate to the patient with early infection treated at home are outlined and the immediate need for management guidance in the setting of widespread hospital resource consumption, morbidity, and mortality is emphasized. Expand
COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review
TLDR
Early use of macrolide use by family practitioners for home treatment of individuals presenting mild or moderate symptoms under rigorous scientific guidance to prevent hospitalisation, death and long-COVID. Expand
Medical management of COVID-19: treatment options under consideration
TLDR
This review has attempted to summate the potential drugs therapies with emphasis on convalescent plasma, and at last, the most awaited thing of this pandemic, COVID-19 vaccine. Expand
Overcoming the therapeutic nihilism of out-of-hospital management of COVID-19 patients
  • S. Meini
  • Medicine
  • American journal of epidemiology
  • 2020
TLDR
Sir, I read with great interest the Risch’s paper on the urgent need to discuss COVID-19 outpatient treatment, and think that any consideration on appropriate treatments must take into account this missing data. Expand
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19).
TLDR
An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death. Expand
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection
TLDR
Clinical evidence suggests lack of benefit from HCQ use for the treatment of hospitalized patients with COVID-19, and FDA has recently revoked the Emergency Use Authorization (EUA) for emergency use of HCQ and chloroquine to treat CO VID-19. Expand
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
TLDR
Exposure to hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. Expand
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
TLDR
Exposure to hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection in this retrospective observational study. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
TLDR
Hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin, which was significantly more efficient for virus elimination. Expand
Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
TLDR
This study provides the first in vivo evidence that zinc sulfate in combination with hydroxychloroquine may play a role in therapeutic management for COVID-19. Expand
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
TLDR
In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits, however, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies. Expand
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
TLDR
No evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19 is found, highlighting the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs. Expand
Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)
TLDR
The trial of Gautret and colleagues, with consideration of the effect sizes, and p-values from multiple models, does not provide sufficient evidence to support wide-scale rollout of HCQ monotherapy for the treatment of COVID-19; larger randomized studies should be considered. Expand
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
TLDR
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with very low fatality rate in patients, retrospectively report on 1061 SARS-CoV-2 positive tested patients. Expand
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
TLDR
Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS-CoV-2-infected rhesus macaques and these data support early remdesavir treatment initiation in COVID-19 patients to prevent progression to severe pneumonia. Expand
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
TLDR
Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length. Expand
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
TLDR
Patients who received hydroxychloroquine for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTC. Expand
Compassionate Use of Remdesivir for Patients with Severe Covid-19
TLDR
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients, and Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesavir therapy. Expand
...
1
2
3
4
5
...